Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Eleanor Malone
A positive opinion in the EU for Shire's Takhzyro and a favorable US advisory committee vote for prucalopride are incremental positives for Takeda's planned acquisition, on which shareholders are likely to vote in the coming weeks.
Sandoz has become the latest firm to sign a settlement agreement over biosimilar Humira with AbbVie, heralding imminent launch in Europe. In the US, it will hold off launching until September 2023.
GlaxoSmithKline, SV Health Investors and Sofinnova are among the backers of a new Oxford-based biotech which has raised $30m in series A financing and boasts a strong line-up of academic founders. CEO Neil Weir outlines Sitryx's raison d'etre.
The two firms hope improvement in the six-minute walk test might be accepted by the US FDA as registrational endpoint for reldesemtiv in spinal muscular atrophy. Blackstone acquires Clarus, while Merck licenses TriNKETs from Dragonfly.
Roche acquires Tusk Therapeutics of the UK for its lead asset; its other activities will continue as Black Belt Therapeutics. Roche sees combo future for Tusk’s cancer immunotherapy with its own portfolio. Total deal value could reach €655m.
Imfinzi will be the fourth PD-1/L1 inhibitor approved for lung cancer in Europe, but AstraZeneca could carve out a niche by being indicated for sequential use following chemoradiation.